David F. Stern PhD

Professor of Pathology; Associate Director, Shared Resources, Yale Cancer Center; Co-Leader, Signal Transduction Research Program, Yale Cancer Center

Departments & Organizations

Yale Combined Program in the Biological and Biomedical Sciences (BBS): Molecular Cell Biology, Genetics and Development | Molecular Medicine, Pharmacology, and Physiology

Office of Student ResearchCancer Center, Yale: Signal TransductionSkin Diseases Research Center, Yale | Pathology: Stern Lab; ExPathSignal Transduction

Research Interests

Cancer Biology; Signal transduction by HER2/ErbB2 and other EGF family receptor tyrosine kinases; EGF family receptors in breast cancer and mammary development; DNA damage checkpoint signaling; Functional and genetic analysis of cancer; Melanoma more...


  • B.S., Massachusetts Institute of Technology, 06/1976
  • Ph.D., University of California, San Diego, 1983

Selected Publications

  • EGF Receptor activates MET through MAP kinases to enhance non-small cell lung carcinoma invasion and brain metastasis. Breindel JL, Haskins JW, Cowell EP, Zhao M, Nguyen DX, Stern DF. Cancer Res. 2013 Jun 21. [Epub ahead of print]
  • MERTK controls melanoma cell migration and survival and differentially regulates cell behavior relative to AXL. Tworkoski KA, Platt JT, Bacchiocchi A, Bosenberg M, Boggon TJ, Stern DF. Pigment Cell Melanoma Res. 2013 Jul;26(4):527-41. doi: 10.1111/pcmr.12110. Epub 2013 May 21. PMID: 23617806 [PubMed - in process]
  • Genotype-selective combination therapies for melanoma identified by high-throughput drug screening. Held MA, Langdon CG, Platt JT, Graham-Steed T, Liu Z, Chakraborty A, Bacchiocchi A, Koo A, Haskins JW, Bosenberg MW, Stern DF. Cancer Discov. 2013 Jan;3(1):52-67. doi: 10.1158/2159-8290.CD-12-0408. Epub 2012 Dec 13. PMID: 23239741 [PubMed - indexed for MEDLINE]



Latest News


Edit Profile